Regenxbio (RGNX) closed at $7.64 on November 13, 2026, down 4.9% from the previous close, on volume of 680,943 shares (30-day average 1,302,576).
Data as of November 13, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 16, 2026 | 16-Oct-26 8 P : 16-Apr-27 8 C : 16-Apr-27 8 P | 900 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 12, 2026. See the 10 largest for 30, 60 and 90 days
REGENXBIO Reports Third Quarter 2026 Financial Results and Operational Highlights
PRNewswire (Thu, 5-Nov 7:05 AM ET)
REGENXBIO to Participate in Stifel 2026 Healthcare Conference
PRNewswire (Tue, 3-Nov 7:05 AM ET)
PRNewswire (Thu, 29-Oct 7:05 AM ET)
Market Chameleon (Tue, 13-Oct 7:16 AM ET)
PRNewswire (Mon, 12-Oct 7:05 AM ET)
PRNewswire (Thu, 24-Sep 7:18 PM ET)
REGENXBIO to Participate in Upcoming Investor Conferences
PRNewswire (Tue, 8-Sep 7:05 AM ET)
Business Wire (Tue, 25-Aug 12:53 PM ET)
REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli
PRNewswire (Tue, 25-Aug 7:05 AM ET)
RGNX Investor Notice: Johnson Fistel Investigates REGENXBIO Inc. Following Clinical Hold
Globe Newswire (Mon, 24-Aug 2:18 PM ET)
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
Regenxbio trades on the NASDAQ stock market under the symbol RGNX.
As of November 13, 2026, RGNX stock price declined to $7.64 with 680,943 million shares trading.
RGNX has a beta of 2.63, meaning it tends to be more sensitive to market movements. RGNX has a correlation of 0.10 to the broad based SPY ETF.
RGNX has a market cap of $504.34 million. This is considered a Small Cap stock.
Last quarter Regenxbio reported $9 million in Revenue and -$.62 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $.69.
In the last 3 years, RGNX traded as high as $28.80 and as low as $5.04.
The top ETF exchange traded funds that RGNX belongs to (by Net Assets): XBI, VTI, IWM, VXF, FESM.
RGNX has underperformed the market in the last year with a return of -34.1%, while the SPY ETF gained +11.5%. In the last 3 month period, RGNX fell short of the market, returning -30.0%, while SPY returned -2.1%. However, in the most recent 2 weeks RGNX has outperformed the stock market by returning +3.1%, while SPY returned -1.9%.
RGNX support price is $7.63 and resistance is $8.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RGNX shares will trade within this expected range on the day.
